시장보고서
상품코드
1322268

세계의 근위축성 측색 경화증(ALS, 루게릭병) 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2031년)

Amyotrophic Lateral Sclerosis Treatment Market (Type: Sporadic ALS and Familial ALS; Treatment: Medication, Stem Cell Therapy, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

발행일: | 리서치사: Transparency Market Research | 페이지 정보: 영문 195 Pages | 배송안내 : 2-10일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

근위축성 측색 경화증 치료 시장-보고서 범위

세계의 근위축성 측색 경화증(ALS, 루게릭병) 치료(Amyotrophic Lateral Sclerosis Treatment) 시장에 대한 TMR 보고서는 과거 및 현재의 성장 동향과 2023년에서 2031년까지의 예측 기간 동안 시장 지표의 귀중한 통찰력을 얻을 기회를 연구합니다. 이 보고서는 2023년을 기준년도, 2031년을 예측년도로 하여, 2017년부터 2031년까지의 근위축성 측색 경화증 치료 시장의 수익을 게재합니다. 또한 2023년부터 2031년까지 세계의 근위축성 측색 경화증 치료 시장의 CAGR(%)도 제공합니다.

보고서는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서는 조사 활동의 대부분이 이루어졌으며 분석가들은 주요 오피니언 리더, 산업 리더, 오피니언 제조사와 인터뷰를 실시했습니다. 2차 조사에는 근위축성 측색 경화증 치료 시장을 이해하기 위해 주요 기업의 제품 문헌, 연례 보고서, 보도 자료 및 관련 문서에 대한 참조가 포함됩니다.

세계의 근위축성 측색 경화증 치료 시장 경쟁 상황을 파악하고 있습니다. 세계 근위축성 측색 경화증 치료 시장에서 활동하는 주요 플레이어가 확인되었으며, 이들 각각은 다양한 속성 관점에서 프로파일링됩니다. 회사 개요, 재무 상황, 최근 동향, SWOT는 이 보고서에 소개 된 세계의 근위축성 측색 경화증 치료 시장 플레이어의 속성입니다.

목차

제1장 서문

제2장 전제 조건 및 연구 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

  • 소개
  • 개요
  • 시장 역학
  • 전 세계 시장 분석 및 예측(2017-2031년)

제5장 주요 통찰

  • 지역별/세계 전체의 규제 시나리오
  • 파이프라인 분석
  • 가격 분석
  • COVID-19의 팬데믹이 산업에 미치는 영향

제6장 시장 분석 및 예측 : 유형별

  • 소개 및 정의
  • 주요 결과 및 개발
  • 시장 금액 예측 : 유형별(2017-2031년)
    • 산발성 ALS
    • 가족성 ALS
  • 시장 매력 분석 : 유형별

제7장 시장 분석 및 예측 : 치료법별

  • 소개 및 정의
  • 주요 결과 및 개발
  • 시장 금액 예측 : 치료별(2017-2031년)
    • 투약
    • 줄기세포치료
    • 기타
  • 시장 매력 분석 : 치료법별

제8장 시장 분석 및 예측 : 유통 채널별

  • 소개 및 정의
  • 주요 결과 및 개발
  • 시장 금액 예측 : 유통 채널별(2017-2031년)
    • 병원 약국
    • 소매 약국
    • 기타
  • 시장 매력 분석 : 유통 채널별

제9장 시장 분석 및 예측 : 지역별

  • 주요 조사 결과
  • 시장 금액 예측 : 지역별
    • 북미
    • 유럽
    • 아시아 태평양 지역
    • 남미
    • 중동 및 아프리카
  • 시장 매력 분석 : 지역별

제10장 북미 시장 분석 및 예측

제11장 유럽 시장 분석 및 예측

제12장 아시아 태평양 시장 분석 및 예측

제13장 남미 시장 분석 및 예측

제14장 중동 및 아프리카 시장 분석 및 예측

제15장 경쟁 상황

  • 시장 진입 기업-경쟁 매트릭스(기업의 계층 및 규모별)
  • 시장 점유율 분석 : 기업별(2022년)
  • 기업 개요
    • Mitsubishi Tanabe Pharma Corporation
    • Otsuka Pharmaceutical Co., Ltd.
    • BrainStorm Therapeutics
    • Biogen, Inc.
    • Corestem
    • AB Science
    • F. Hoffmann-La Roche AG
    • Biohaven Pharmaceutical
    • Sun Pharmaceutical
    • Other Prominent Players
LYJ 23.10.10

Amyotrophic Lateral Sclerosis Treatment Market - Scope of Report

TMR's report on the global Amyotrophic Lateral Sclerosis Treatment Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Amyotrophic Lateral Sclerosis Treatment Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Amyotrophic Lateral Sclerosis Treatment Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Amyotrophic Lateral Sclerosis Treatment Market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Amyotrophic Lateral Sclerosis Treatment Market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Amyotrophic Lateral Sclerosis Treatment Market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Amyotrophic Lateral Sclerosis Treatment Market.

The report delves into the competitive landscape of the global Amyotrophic Lateral Sclerosis Treatment Market. Key players operating in the global Amyotrophic Lateral Sclerosis Treatment Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Amyotrophic Lateral Sclerosis Treatment Market profiled in this report.

Key Questions Answered in Global Amyotrophic Lateral Sclerosis Treatment Market Report:

  • What is the sales/revenue generated by mobile photo printer across all regions during the forecast period?
  • What are the opportunities in the global Amyotrophic Lateral Sclerosis Treatment Market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Amyotrophic Lateral Sclerosis Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global Amyotrophic Lateral Sclerosis Treatment Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Amyotrophic Lateral Sclerosis Treatment Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Amyotrophic Lateral Sclerosis Treatment.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Amyotrophic Lateral Sclerosis Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Regulatory Scenario by Region/globally
  • 5.2. Pipeline Analysis
  • 5.3. Pricing Analysis
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Type, 2017-2031
    • 6.3.1. Sporadic ALS
    • 6.3.2. Familial ALS
  • 6.4. Market Attractiveness Analysis, by Type

7. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, by Treatment

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Treatment, 2017-2031
    • 7.3.1. Medication
    • 7.3.2. Stem Cell Therapy
    • 7.3.3. Others
  • 7.4. Market Attractiveness Analysis, by Treatment

8. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Type, 2017-2031
    • 10.2.1. Sporadic ALS
    • 10.2.2. Familial ALS
  • 10.3. Market Value Forecast, by Treatment, 2017-2031
    • 10.3.1. Medication
    • 10.3.2. Stem Cell Therapy
    • 10.3.3. Others
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Type
    • 10.6.2. By Treatment
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Type, 2017-2031
    • 11.2.1. Sporadic ALS
    • 11.2.2. Familial ALS
  • 11.3. Market Value Forecast, by Treatment, 2017-2031
    • 11.3.1. Medication
    • 11.3.2. Stem Cell Therapy
    • 11.3.3. Others
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Type
    • 11.6.2. By Treatment
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Type, 2017-2031
    • 12.2.1. Sporadic ALS
    • 12.2.2. Familial ALS
  • 12.3. Market Value Forecast, by Treatment, 2017-2031
    • 12.3.1. Medication
    • 12.3.2. Stem Cell Therapy
    • 12.3.3. Others
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Type
    • 12.6.2. By Treatment
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Type, 2017-2031
    • 13.2.1. Sporadic ALS
    • 13.2.2. Familial ALS
  • 13.3. Market Value Forecast, by Treatment, 2017-2031
    • 13.3.1. Medication
    • 13.3.2. Stem Cell Therapy
    • 13.3.3. Others
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Type
    • 13.6.2. By Treatment
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Type, 2017-2031
    • 14.2.1. Sporadic ALS
    • 14.2.2. Familial ALS
  • 14.3. Market Value Forecast, by Treatment, 2017-2031
    • 14.3.1. Medication
    • 14.3.2. Stem Cell Therapy
    • 14.3.3. Others
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Type
    • 14.6.2. By Treatment
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2022
  • 15.3. Company Profiles
    • 15.3.1. Mitsubishi Tanabe Pharma Corporation
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Otsuka Pharmaceutical Co., Ltd.
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. BrainStorm Therapeutics
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Biogen, Inc.
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Corestem
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. AB Science
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. F. Hoffmann-La Roche AG
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Biohaven Pharmaceutical
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Sun Pharmaceutical
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Other Prominent Players
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제